The Ninth Visual Object Tracking VOT2021 Challenge Results

acceptedVersionPeer reviewe

Clinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients.

BACKGROUND: Until now there has been scarce evidence regarding an optimal antiplatelet strategy and clinical outcomes for patients who had suffered from stent thrombosis (ST). METHODS AND RESULTS: 140 patients who suffered from stent thrombosis were prospectively registered. Patients received dual (aspirin and 150 mg clopidogrel, N = 66) or triple (additional cilostazol, N = 74) antiplatelet therapy at the physician's discretion. Thereafter platelet reactivity and one year clinical outcomes were analyzed. The primary outcome included the composite of cardiac death, non-fatal myocardial infarction (MI) or stroke at one year,which developed in 41 (29.3%) patients, consisting of 31 (22.1%) cardiac death, 9 (6.4%) non-fatal MI and 1 (1.4%) stroke. Recurrent definite and probable ST according to ARC definition was observed in 8 (5.7%) and 14 (10.0%) patients, respectively. Triple therapy was associated with significantly lower platelet reactivities (50.2 ± 17.8, % vs. 59.6 ± 17.2, %, P = 0.002) compared to high dose dual antiplatelet therapy. However, the incidence of primary events (24.3% vs. 34.8%, P = 0.172) did not differ between triple and dual antiplatelet therapies. High on-treatment platelet reactivity (HR: 8.35, 95% CI: 2.234∼30.867, P = 0.002) and diabetes (HR: 3.732, 95% CI: 1.353∼10.298, P = 0.011) were independent predictors of primary events. CONCLUSIONS: Patients who suffered from stent thrombosis have a poor prognosis even after revascularization with intensive antiplatelet therapy. Triple antiplatelet therapy was more effective in reducing on-treatment platelet reactivity, compared to high dose dual antiplatelet therapy

IL-22 is required for Th17 cell–mediated pathology in a mouse model of psoriasis-like skin inflammation

Psoriasis is a chronic skin disease resulting from the dysregulated interplay between keratinocytes and infiltrating immune cells. We report on a psoriasis-like disease model, which is induced by the transfer of CD4+CD45RBhiCD25– cells to pathogen-free scid/scid mice. Psoriasis-like lesions had elevated levels of antimicrobial peptide and proinflammatory cytokine mRNA. Also, similar to psoriasis, disease progression in this model was dependent on the p40 common to IL-12 and IL-23. To investigate the role of IL-22, a Th17 cytokine, in disease progression, mice were treated with IL-22–neutralizing antibodies. Neutralization of IL-22 prevented the development of disease, reducing acanthosis (thickening of the skin), inflammatory infiltrates, and expression of Th17 cytokines. Direct administration of IL-22 into the skin of normal mice induced both antimicrobial peptide and proinflammatory cytokine gene expression. Our data suggest that IL-22, which acts on keratinocytes and other nonhematopoietic cells, is required for development of the autoreactive Th17 cell–dependent disease in this model of skin inflammation. We propose that IL-22 antagonism might be a promising therapy for the treatment of human psoriasis

Half-Century of Scientific Advancements Since the Cooperative Study of the Kuroshio and Adjacent Regions (CSK) Programme-Need for a new Kuroshio Research

Through the Cooperative Study of the Kuroshio and Adjacent Regions (CSK) program during 1965 & ndash;1979, the capacities of current member states (MSs) of the Sub-Commission for the Western Pacific (WESTPAC) of the Intergovernmental Oceanographic Commission (IOC) were enhanced with regard to regional ocean science and data management. Following the termination of the CSK in 1979, each MS continued the work to advance ocean science. The results of scientific studies of the Kuroshio and its adjacent regions have been published by various experts including many from the MSs of the WESTPAC; however, to-date, there has been no systematic approach to the research of the Kuroshio and its adjacent regions. This review considered the Kuroshio from the regional perspective of experts of the MSs, that is, from the perspectives of MSs, science, and the future prospects. Experts from each MS reviewed past activities and contributions and reviewed the knowledge gaps in the fields of physical, biological, and biogeochemical science. Many scientific questions remain regarding the path of the Kuroshio from south to north, as well as associated phenomena, including mesoscale eddies and fronts, the important roles of ocean variations in adjacent regions, and the different roles and mechanisms of air & ndash;sea interactions in low-and mid-latitude areas. Despite considerable effort by many biologists, substantial gaps remain in our biological knowledge of the region. The Kuroshio and its adjacent regions comprise one of the areas of the world with high biodiversity; however, there has been insufficient research into what is the cause of this high biodiversity. From a biogeochemical aspect, high resolution spatiotemporal observations will be required to understand interactions with physical processes both in the Kuroshio region and in the marginal seas. It has been highlighted that long-term fixed-location observations will be needed to understand the key mechanisms of biogeochemical processes, particularly in relation to climate change. Finally, the report summarized the future perspectives. Based on recognition of the current circumstances and with acknowledgment of the potential short-term future capabilities of MSs, the possible uses of new technologies and frameworks were discussed. Since the implementation of the United Nations Convention on the Law of the Sea, which came into force in 1994, it has been difficult to conduct observations in the exclusive economic zone (EEZ) of other regional states. Thus, new frameworks and/or technologies will be needed to ensure the success of future studies of the Kuroshio

Changes of PA in dual and triple antiplatelet therapy.

<p>Before treatment PA was performed before clinical treatment, after treatment PA was performed after 7 days under intensive therapy (^*Triple-After treatment vs. Dual-After treatment, P = 0.002).</p

Baseline angiographic and PCI results.

<p>Values were presented as number (%) and mean±SD. PCI, percutaneous coronary intervention, LMWH, low molecular weight heparin.</p